Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Favorable outcomes of potassium-competitive acid blocker (PCAB)-containing eradication therapy have been reported. In fact, tegoprazan, a recently developed PCAB, was presumed to show good eradication efficacy even for resistant Helicobacter pylori. We aimed to investigate the anti-H. pylori efficacy of tegoprazan compared with that of vonoprazan. Methods: A total of 220 resistant clinical H. pylori isolates were utilized. The anti-H. pylori efficacy of PCABs was determined by evaluating the minimum inhibitory concentrations (MICs) of clarithromycin, fluoroquinolone, metronidazole, and amoxicillin in combination with vonoprazan or tegoprazan by the agar dilution method. The impact of the mutations responsible for resistance development, such as 23S rRNA, gyrA, rdxA, frxA, and pbp1 mutations, was also analyzed. Results: H. pylori growth was significantly inhibited in a medium containing 1 μg/mL clarithromycin with tegoprazan (128 μg/mL). The MICs of clarithromycin (46.3%), fluoroquinolone (46.7%), metronidazole (55.6%), and amoxicillin (34.5%) against resistant H. pylori isolates improved after tegoprazan administration. Tegoprazan demonstrated more frequent susceptibility acquisition with metronidazole than with vonoprazan (20.6% vs 4.7%, p=0.014). However, there were no significant differences depending on the mutational status of each antimicrobial agent. Conclusions: Tegoprazan administration may improve the susceptibility of antimicrobial-resistant H. pylori, independent of acid suppression.
Abstract
Background/Aims: Favorable outcomes of potassium-competitive acid blocker (PCAB)-containing eradication therapy have been reported. In fact, tegoprazan, a recently developed PCAB, was presumed to show good eradication efficacy even for resistant Helicobacter pylori. We aimed to investigate the anti-H. pylori efficacy of tegoprazan compared with that of vonoprazan. Methods: A total of 220 resistant clinical H. pylori isolates were utilized. The anti-H. pylori efficacy of PCABs was determined by evaluating the minimum inhibitory concentrations (MICs) of clarithromycin, fluoroquinolone, metronidazole, and amoxicillin in combination with vonoprazan or tegoprazan by the agar dilution method. The impact of the mutations responsible for resistance development, such as 23S rRNA, gyrA, rdxA, frxA, and pbp1 mutations, was also analyzed. Results: H. pylori growth was significantly inhibited in a medium containing 1 μg/mL clarithromycin with tegoprazan (128 μg/mL). The MICs of clarithromycin (46.3%), fluoroquinolone (46.7%), metronidazole (55.6%), and amoxicillin (34.5%) against resistant H. pylori isolates improved after tegoprazan administration. Tegoprazan demonstrated more frequent susceptibility acquisition with metronidazole than with vonoprazan (20.6% vs 4.7%, p=0.014). However, there were no significant differences depending on the mutational status of each antimicrobial agent. Conclusions: Tegoprazan administration may improve the susceptibility of antimicrobial-resistant H. pylori, independent of acid suppression.
참고문헌 (24)
- Sugano K, "Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease : safety and clinical evidence to date", Therap Adv Gastroenterol, 11, pp.1756283~ (2018)
- Jung YS, "Systematic review with metaanalysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication", Aliment Pharmacol Ther, 46, pp.106~114 (2017)
- Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
- Scarpignato C, "Editorial : potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block", Aliment Pharmacol Ther, 50, pp.960~962 (2019)
- Han S, "Randomised clinical trial : safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 50, pp.751~759 (2019)
- Lee KJ, "Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
- Lee JW, "High efficacy of finafloxacin on Helicobacter pylori isolates at pH 5. 0 compared with that of other fluoroquinolones", Antimicrob Agents Chemother, 59, pp.7629~7636 (2015)
- Lee JW, "Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea", Helicobacter, 16, pp.301~310 (2011)
- Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea", J Clin Gastroenterol, 44, pp.536~543 (2010)
- Kwon YH, "Specific mutations of penicillin-binding protein 1A in 77 clinically acquired amoxicillinresistant Helicobacter pylori strains in comparison with 77amoxicillin-susceptible strains", Helicobacter, 22, pp.e12437~ (2017)
- Lee SM, "rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori : their relation to clinical outcomes", J Gastroenterol Hepatol, 33, pp.681~688 (2018)
- Tankovic J, "Single and double mutations in gyrA but not in gyrB are associated with low-and high-level fluoroquinolone resistance in Helicobacter pylori", Antimicrob Agents Chemother, 47, pp.3942~3944 (2003)
- Lee JW, "Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance", Helicobacter, 24, pp.e12561~ (2019)
- Villoria A, "Metaanalysis : high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication", Aliment Pharmacol Ther, 28, pp.868~877 (2008)
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Gatta L, "Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection", Am J Gastroenterol, 99, pp.823~829 (2004)
- Choi HS, "Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate", Helicobacter, 12, pp.638~642 (2007)
- Graham DY, "Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors", Am J Gastroenterol, 98, pp.1005~1009 (2003)
- 윤기철, "연속요법의 Helicobacter pylori 제균율 - 3차 기관에서의 8년간의 전향적 연구", 대한소화기학회지, 73(2), pp.99~104 (2019), 대한소화기학회
- Lee JW, "A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea", Scand J Gastroenterol, 49, pp.917~924 (2014)
- Yoon H, "Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?", J Gastroenterol Hepatol, 28, pp.1801~1809 (2013)
- Gatta L, "Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori", J Antimicrob Chemother, 51, pp.439~442 (2003)
- Francesco VD, "Mechanisms of Helicobacter pylori antibiotic resistance : an updated appraisal", World J Gastrointest Pathophysiol, 2, pp.35~41 (2011)
- Hirata K, "Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori", J Gastroenterol Hepatol, 25(Suppl 1), pp.S75~S79 (2010)